Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) had a rough 2011. If the pre-market trading indications manage to last throughout the day, then it appears that Teva could be off to a great start in 2012. The company just announced that it will have a new Chief Executive Officer. Whether you look at Teva for its generic gains or its branded products, this may matter. The company’s current CEO will retire in May and will be replaced by Jeremy Levin upon retirement. Teva was well above $50 throughout much of early 2011 and ended up going under $40.00 before recovering. Shares closed out at $40.36 on Friday and the stock is indicated up 3.6% at $41.82 so far this Tuesday morning to start of 2012.
JON C. OGG
“The Next NVIDIA” Could Change Your Life
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
